Alkermes PLC (NASDAQ:ALKS) Director Paul J. Mitchell sold 1,500 shares of the stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $58.11, for a total transaction of $87,165.00. Following the completion of the sale, the director now directly owns 9,500 shares in the company, valued at $552,045. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of Alkermes PLC (NASDAQ ALKS) opened at 59.66 on Tuesday. Alkermes PLC has a 52 week low of $41.93 and a 52 week high of $63.40. The company has a 50-day moving average price of $58.44 and a 200-day moving average price of $57.27. The stock’s market cap is $9.14 billion.
Alkermes PLC (NASDAQ:ALKS) last announced its quarterly earnings data on Thursday, April 27th. The company reported ($0.31) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by $0.07. The business had revenue of $191.80 million during the quarter, compared to the consensus estimate of $195.79 million. Alkermes PLC had a negative net margin of 25.61% and a negative return on equity of 9.76%. The business’s revenue was up 22.3% compared to the same quarter last year. During the same period last year, the company earned ($0.16) EPS. Equities analysts anticipate that Alkermes PLC will post ($0.04) EPS for the current year.
WARNING: “Paul J. Mitchell Sells 1,500 Shares of Alkermes PLC (ALKS) Stock” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.chaffeybreeze.com/2017/07/18/alkermes-plc-alks-director-paul-j-mitchell-sells-1500-shares-of-stock-updated.html.
Institutional investors have recently made changes to their positions in the stock. FMR LLC increased its position in shares of Alkermes PLC by 0.4% in the first quarter. FMR LLC now owns 22,882,118 shares of the company’s stock valued at $1,338,604,000 after buying an additional 86,546 shares during the period. Vanguard Group Inc. boosted its stake in shares of Alkermes PLC by 4.3% in the first quarter. Vanguard Group Inc. now owns 12,096,635 shares of the company’s stock valued at $707,654,000 after buying an additional 497,421 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Alkermes PLC by 5,927.5% in the first quarter. BlackRock Inc. now owns 10,292,601 shares of the company’s stock valued at $602,115,000 after buying an additional 10,121,839 shares in the last quarter. Primecap Management Co. CA boosted its stake in shares of Alkermes PLC by 23.2% in the first quarter. Primecap Management Co. CA now owns 7,856,543 shares of the company’s stock valued at $459,608,000 after buying an additional 1,480,273 shares in the last quarter. Finally, Woodford Investment Management Ltd boosted its stake in shares of Alkermes PLC by 0.3% in the first quarter. Woodford Investment Management Ltd now owns 7,470,528 shares of the company’s stock valued at $437,026,000 after buying an additional 19,400 shares in the last quarter. 97.24% of the stock is currently owned by institutional investors.
A number of brokerages have recently issued reports on ALKS. Cowen and Company reissued a “positive” rating and issued a $65.00 price target on shares of Alkermes PLC in a report on Tuesday, March 21st. ValuEngine raised shares of Alkermes PLC from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Leerink Swann cut shares of Alkermes PLC from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $68.00 to $61.00 in a research report on Tuesday, June 13th. Credit Suisse Group restated a “buy” rating and issued a $70.00 price objective on shares of Alkermes PLC in a research report on Wednesday, June 7th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $70.00 price objective on shares of Alkermes PLC in a research report on Monday, April 3rd. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $62.55.
About Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.